Inclusion Criteria:

          1. Written informed consent and HIPAA authorization for release of personal health
             information.

          2. Age > 18 years at the time of consent.

          3. ECOG Performance Status of 0-1 within 14 days prior to being registered for protocol
             therapy (Study Procedure Manual).

          4. Histologically confirmed adenocarcinoma of the prostate (with previous diagnostic
             tissue available for tumor marker analysis).

          5. Gleason 7 - 10, cT2a - cT3b adenocarcinoma of the prostate with plans for radical
             prostatectomy

          6. PSA ≥ 4 ng/ml

          7. Tumor visible on multiparametric MRI

          8. Tolerated previous transrectal ultrasound guided biopsy procedure under local
             anesthetic

             a. Uncomplicated previous TRUS biopsy procedure (i.e., no prior hospitalization due to
             sepsis, prostatic abscess or severe hemorrhage following TRUS prostate biopsy)

          9. Willing to undergo the intra-tumoral (IT) injection of the Poly-ICLC into the
             prostatic tumor as per the protocol

         10. No prior hormonal therapy with the exception of oral 5-alpha-reductase inhibitors
             (finasteride, dutasteride, etc.). Patients who have received prior oral anti-androgen
             therapies (bicalutamide, flutamide, nilutamide, etc.) must be off treatment for at
             least 6 weeks prior to enrollment. Patients who have received prior LHRH agonist or
             antagonist therapy (leuprolide, goserelin acetate, etc.) are eligible provided serum
             testosterone is > 50 mg/dl.

         11. No prior radiation therapy (external beam or brachytherapy) to the pelvis or prostate.

         12. No clinically significant infections as judged by the treating investigator.

         13. No characteristics suggesting a potential higher risk of infection with intraprostatic
             injections:

               1. Recurrent urinary tract infections or history of prostatitis within 3 months
                  prior to enrollment into the study.

               2. Urine analysis positive for nitrites and leucocyte esterase. Such patients could
                  be considered for the study after treatment and resolution of the infection.

               3. Active proctitis

               4. History of prostatic abscess

               5. Taking immunosuppressive medication including systemic corticosteroids

               6. Active hematologic malignancy

         14. No uncontrolled angina, congestive heart failure or MI within 6 months.

         15. Patients with history of HIV (if CD4+ T cell counts are ≥350 cells/µL on established
             ART therapy), Hepatitis B (with viral load below limits of quantification) or
             Hepatitis C (who have completed a curative therapy and have a viral load below the
             limit of quantification) are eligible for this study.

         16. No treatment with any investigational agent for any medical condition within 28 days
             prior to being registered for protocol therapy.

         17. Adequate end organ function as determined by the following laboratory values:

               -  White blood cell count (WBC) > 2.5 k/mm3

               -  Absolute neutrophil count (ANC) > 1.5 k/mm3

               -  Hemoglobin (Hgb) > 8.0 g/dL

               -  Platelets > 100 k/mm3

               -  Calculated creatinine clearance of > 60 cc/min using the Cockcroft-Gault formula:

             Males: (140 - Age in years) × Actual Body Weight in kg 72 × Serum Creatinine (mg/dL)

               -  Bilirubin < 2.0 x ULN

               -  Aspartate aminotransferase (AST) < 2.5 x ULN

               -  Alanine aminotransferase (ALT) < 2.5 x ULN

         18. Able to speak, read and write in English.